Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IONS shares.
View IONS analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $65.00. On average, they predict the company's share price to reach $48.10 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $30.43 at the beginning of 2022. Since then, IONS stock has increased by 45.3% and is now trading at $44.23.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.13. The business earned $134 million during the quarter, compared to analyst estimates of $142.65 million. Ionis Pharmaceuticals had a negative net margin of 3.18% and a negative trailing twelve-month return on equity of 4.10%. The business's revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) earnings per share.

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $610.05 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $44.23.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.28 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.